Cancer Genetics Inc (CGIX)

[chmcnfunds]

Cancer Genetics to Provide Genetic Testing Platform to NextGxDx

Cancer Genetics’ proprietary oncology tests and services to be featured in online test marketplace

RUTHERFORD, NJ (September 9, 2013):

Cancer Genetics, Inc. (NASDAQ: CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the diagnosis and prediction of treatment outcomes for difficult to diagnose cancers, today announced an agreement with NextGxDx Inc. which provides an online genetic testing marketplace for healthcare professionals and hospitals. Through this agreement, NextGxDx will offer Cancer Genetics’ genomic-based, proprietary oncology tests and services through its platform.

“Genetic testing within oncology is evolving at a tremendous rate,” said NextGxDx CEO Mark Harris, PhD, MBA. “Our newest partner, Cancer Genetics, provides our growing marketplace with a robust catalog of more than 100 regulatory approved oncology testing products and solutions for easy search, comparison and ordering.”

Cancer Genetics is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. The company is focused on transforming diagnosis and disease management for the most complex and difficult-to-treat cancers, including hematologic, urogenital, and gynecological malignancies.

“Our team takes tremendous pride in our focus on personalizing the diagnosis for cancer patients,” said Panna Sharma, CEO of Cancer Genetics, Inc. “The NextGxDx platform supports our mission by enhancing our market reach while allowing us to focus on delivering critical genomic information through our clinical trial services and proprietary testing, where patients and their physicians need it most — to diagnose, monitor and inform cancer treatment.”

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics that personalizes the diagnosis and prediction of treatment outcomes for difficult to diagnose cancers. These cancers include hematological, urogenital and HPV-associated cancers. The Company’s comprehensive range of oncology-focused tests and laboratory services provide critical genomic information to healthcare professionals, cancer centers, and biopharma companies. Through its CLIA certified and CAP accredited state-of-the-art reference lab, Cancer Genetics services some of the most prestigious medical institutions in the world and has strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.

About NextGxDx:

NextGxDx, Inc. provides an online genetic testing marketplace that offers healthcare professionals and hospitals the ability to access up-to-date listings of all genetic tests from CLIA-certified laboratories, view pertinent information about each test, order tests online, and manage results electronically within the HIPAA-compliant portal. By providing clinicians with a one-stop-shop to search, compare and order genetic tests, NextGxDx reduces the time and costs associated with the ordering of genetic tests. For more information, visit www.NextGxDx.com.

Contact Information:
Marie-Agnes Patrone-Michellod
Marketing and Regulatory Manager
[e-mail]

Released September 9, 2013
______________________________________________________
http://ir.cancergenetics.com/company-news/detail/314

News from yesterday as released by CGIC

CGIX